Silicosis laboratory findings

Jump to navigation Jump to search

Silicosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Silicosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Silicosis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Silicosis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Silicosis laboratory findings

CDC on Silicosis laboratory findings

Silicosis laboratory findings in the news

Blogs on Silicosis laboratory findings

Directions to Hospitals Treating Silicosis

Risk calculators and risk factors for Silicosis laboratory findings

There are no laboratory tests for the diagnosis of acute silicoproteinosis. However, a complete blood count and differential, brain natriuretic peptide, granulocyte macrophage-colony stimulating factor (GM-CSF) antibodies, and cultures of blood and sputum are helpful in excluding processes in the differential diagnosis.

Assessment of oxygenation is important, either with pulse oxygen saturation or arterial blood gas, to determine the severity of respiratory impairment and whether the patient will be able to tolerate diagnostic procedures. When chronic silicosis is suspected due to the onset of respiratory symptoms (eg, dyspnea, productive cough) or typical chest imaging findings, the evaluation is aimed at confirming the exposure history, assessing the degree of respiratory impairment, and excluding other causes. A careful occupational history is essential, as described above. (See 'Silica in the work environment' above.)

Laboratory testing — There are no laboratory tests for the diagnosis of chronic silicosis. As mycobacterial infection is often in the differential diagnosis or may develop as a complication, testing for latent tuberculosis via skin test or interferon release assay is often obtained. In addition, sputum smear and culture for mycobacteria are obtained in the presence of fever, weight loss, hemoptysis, or complicated silicosis on radiographic imaging.


Imaging — A chest radiograph is obtained in virtually all patients undergoing evaluation for chronic silicosis; high resolution computed tomography (HRCT) is helpful for patients with an atypical clinical presentation or atypical findings on chest radiograph. In our occupational lung disease specialty clinic, we often obtain a baseline HRCT scan in patients with radiographic findings of silicosis to document the presence and extent of nodules, emphysema, and other silica-related abnormalities that may progress in the future.

●Chest radiograph – The typical chest radiograph finding in chronic simple silicosis is the presence of innumerable, small, rounded opacities (less than 10 mm in diameter). The nodules are generally rounded but can be irregular, and are distributed predominantly in the upper lung zones (image 3A-B). Progressive massive fibrosis (PMF, also known as conglomerate silicosis) occurs when these small opacities gradually enlarge and coalesce to form larger, upper- or mid-zone opacities more than 10 mm in diameter (image 4) [22]. As these opacities progressively enlarge, the hila are retracted upward in association with upper lobe fibrosis and lower lobe hyperinflation. The opacities of PMF can be asymmetrical, and may mimic a neoplastic process. Cavitation may also be present in advanced disease or in the setting of mycobacterial superinfection. Hilar adenopathy with prominent calcification is present in up to 5 percent of workers with silicosis. (See "Imaging of occupational lung diseases", section on 'Silicosis'.)

Several reports have compared the accuracy of the chest radiograph appearance to pathologic examination of the lungs at autopsy in detecting silicosis. In a study of more than 500 South African gold miners, when radiographs were scored using the International Labor Office (ILO) classification system profusion classes of 1/0, 1/1, and 1/2 as cutoffs, sensitivities were found to be 50, 37, and 25 percent, respectively, and specificities 89, 96, and 100 percent, respectively [72]. A subsequent smaller study of 241 South African gold miners evaluated use of "miniradiographs" with cutoffs at ILO profusion categories 0/1, 1/0, and 1/1. Sensitivities were 89, 74, and 71 percent, respectively, and specificities were 73, 87, and 96 percent, respectively [73]. Reasons for improved sensitivity in the second study were unclear. (See "Imaging of occupational lung diseases", section on 'The International Labor Office classification' and "Evaluation of diffuse lung disease by conventional chest radiography".)

●High resolution computed tomography – HRCT is usually not necessary in simple silicosis unless atypical clinical or radiographic features are noted (eg, fever, spiculated nodules, a single nodule of substantially larger size than the others). However, HRCT has been shown to improve sensitivity and significantly reduce inter-reader variability compared to conventional radiography [74,75]. The typical HRCT findings in simple silicosis are bilateral, symmetric, centrilobular, and perilymphatic nodules with sharp margination (image 5). These nodules calcify in 10 to 20 percent of patients.

HRCT is superior to conventional chest radiography for documentation of conglomerate lesions and emphysematous changes associated with complicated silicosis (image 6) [68-71,76-78]. (See "High resolution computed tomography of the lungs".)

Although pleural effusions are unusual, pleural thickening appears to be common, especially among patients with more severe disease. In a series of 110 patients with biopsy proven silicosis followed for a mean of 14 years, pleural effusions were noted in 12 patients (11 percent), but pleural thickening was present in 64 patients (58 percent) [79].

●FDG-PET scan – Fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) scans are often used to differentiate benign from malignant lung lesions. However, FDG-PET is often positive in PMF in the absence of malignancy or infection. The uptake of PMF lesions on FDG-PET scans was evaluated in a series of nine patients with 14 masses, ranging in size from 1.2 to 6.4 cm in maximum diameter [80]. The maximal standard uptake value (SUV) ranged from 3.1 to 14.6 and mean SUV ranged from 1.4 to 8.5. An SUV exceeding 2.5 is generally considered highly suggestive of malignancy or active inflammation. (See "Computed tomographic and positron emission tomographic scanning of pulmonary nodules", section on 'Positron emission tomography (PET)'.)

Bronchoscopy — Flexible bronchoscopy has a limited diagnostic role in chronic silicosis, and, for most patients, bronchoscopy to confirm the diagnosis is not indicated. However, bronchoscopic washings, brushing, or bronchoalveolar lavage may be used to obtain samples for microbiologic studies and cytology when infection and/or malignancy are in the differential diagnosis based on the imaging results. In general, transbronchial biopsy is avoided in chronic silicosis due to the presumed risk for pneumothorax and the small sample size.

Diagnosis — The diagnosis of acute silicosis is based upon the history of an acute, high dose silica exposure, imaging findings of diffuse nodular and patchy consolidative opacities, a milky, lipoproteinaceous bronchoalveolar lavage effluent, and exclusion of other potential explanations (infection, pulmonary edema, alveolar hemorrhage, eosinophilic pneumonia, primary pulmonary alveolar proteinosis). A lung biopsy is not necessary in the setting of a definite exposure history and these characteristic findings.

Once lipoproteinaceous fluid has been obtained by BAL or observed on biopsy, other causes of alveolar proteinosis or lipidosis are usually identified by history of inhalational exposure (eg, titanium, indium-tin oxide, or aluminum), testing for GM-CSF antibodies, lipid-laden macrophages in bronchoalveolar lavage fluid (suggest lipoid pneumonia), stains and/or cultures obtained from bronchoscopy (eg, Pneumocystis jirovecii or Nocardia), or presence of leukemic cells in the peripheral blood. (See "Diagnosis and treatment of pulmonary alveolar proteinosis in adults", section on 'Evaluation and diagnosis' and "Clinical presentation and diagnosis of Pneumocystis pulmonary infection in HIV-infected patients", section on 'Bronchoalveolar lavage' and "Clinical manifestations and diagnosis of nocardiosis" and "Aspiration pneumonia in adults", section on 'Lipoid pneumonia'.)

References

Template:WH Template:WS